Zephrex-D, Nexafed Make Marketing Pitch As Meth-Fighting Decongestants
This article was originally published in The Pink Sheet Daily
As their technology-enhanced pseudoephedrine decongestant products gain broader distribution, Westport Pharmaceuticals and Acura Pharmaceuticals are educating pharmacists about the drugs’ efficacy for congested consumers and as a means of curbing methamphetamine production.
You may also be interested in...
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
Ohio and West Virginia chain Fruth Pharmacy begins replacing the 30 mg PSE products available in its stores with Acura Pharmaceuticals’ Nexafed product. Meanwhile, DEA says Westport Pharmaceuticals should not make an extraction-proof claim for its Zephrex-D PSE product.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.